Skip to main content

Yesafili News

Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting

FRIDAY, May 9, 2025 – The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to...

FDA Approves Yesafili (aflibercept-jbvf), an Interchangeable Biosimilar to Eylea

May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Macular Degeneration, Macular Edema, Diabetic Macular Edema

Yesafili patient information at Drugs.com